Page 57 - MemoriaDEM-Eng

www.ciberdem.org

Most relevant • RayeGo-Mateos s, MoRGado-PasCual jl, sanz ab, RaMos aM, eGuChI s, batlle d, Pato j, keRI
G, eGIdo j, oRtIz a, RuIz-oRteGa M. TWEAK transactivation of the epidermal growth
scientific
factor receptorJournal of Pathology. 2013; 231: :480–494.
articles
• González-PaRRa e, heRReRo ja, elewa u, bosCh Rj, aRduán ao, eGIdo j. Bisphenol A in
Chronic Kidney DiseaseInternational Journal of Nephrology. 2013;2013(437857).

• R e, k-M M, a-C s, P b, F a, R Fj, C-
aMíRezlettInGoResaRRasCoICatosteeRRaRInIuPéRezaRo
VadIllo a, baRbas C, eGIdo j, tuñón j, loRenzo ó. Eplerenone attenuated cardiac stea-
tosis, apoptosis and diastolic dysfunction in experimental type-II diabetesCardiovas-

cular Diabetology. 2013; 12:172.

• MoReno P, Mantey sa, nuChe-beRenGueR b, ReItMan Ml, González n, Coy dh, jensen Rt..

Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist
MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human

bombesin receptors.J Pharmacol Exp Ther. . 2013; 347:100-16.

• PoRtal-núñez s, CRuCes j, GutIéRRez-Rojas I, lozano d, aRduRa ja, VIllanueVa-PeñaCaRRIllo ó
Ml, d F M, e P.. The vertebrae of prematurely aging mice as a skeletal
ela uentesbRIt
model of involutional osteoporosis.Histol Histopathol. . 2013;28:1473-81.

PROJECTS:
Highlights
• Project Title: Diabetes Cancer Connect: Targeting common inflammatory mark-
ers and signaling pathways in cancer and diabetes mellitus. Role: Principal In-

vestigator in the Integrated Project for Excellence in Research Institutes Accred-

ited, Coordinated by Dr. Jesús Egido Rivers. Funding Agency: Institute of Health
Carlos III (PIE 13/00051). Financing: 800.000 €. Duration (funding period): 3

years (2014-2016).

• Project Title: Study on the role of bombesin receptor subtype-3 in human adi-

pose tissue: potential use as a therapeutic target in obesity and diabetes. Role:
Principal Investigator. Funding Agency: Mutua Madrileña (12224/2). Funding:

20,000 €. Duration (funding period): 2 years (2013-2014).

PATENT PREPARATION:

• SOCS 1 derived peptide for use in chronic complications of diabetes. In col-

laboration with our center (Carmen Gomez-Guerrero and Jesus Egido) and the
Diabetes Research Center of the Vall d’Hebron (Cristina Hernandez and Rafael

Sim).

13
20
T
OR
P
RE
L
A
NU
N
A
M /
E
D
ER
B
CI

57